pith. machine review for the scientific record. sign in

arxiv: 2604.25951 · v1 · submitted 2026-04-23 · 🧮 math.GM

Recognition: unknown

Measles Resurgence in Bangladesh, 2026: A Situational Analysis for Urgent Public Health Response

Alvi Ahmed Sarker, Faizunnesa Khondaker, Md. Kamrujjaman, Nuzhat Nuari Khan Rivu

Pith reviewed 2026-05-08 12:51 UTC · model grok-4.3

classification 🧮 math.GM
keywords measlesresurgenceBangladeshvaccination coverageimmunity gapsoutbreak analysispublic healthsituational review
0
0 comments X

The pith

Bangladesh's measles resurgence in 2026 stems from immunity gaps due to coverage declines and program disruptions, not vaccine failure.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper conducts a situational analysis of the measles outbreak that began in Bangladesh in March 2026. It reports nearly 20,000 suspected cases and dozens of deaths, concentrated in a few divisions and striking mostly unvaccinated children under five. The authors conclude that years of falling routine vaccination rates, subnational inequities, and pandemic-related disruptions have left millions of children susceptible, allowing transmission to resume. They argue this is an issue of accumulated immunity gaps rather than any problem with the vaccines themselves. The analysis identifies urgent steps to restore protection and manage the concentrated outbreak.

Core claim

By mid-April 2026 Bangladesh had recorded 19,161 suspected measles cases, 2,973 confirmed cases, and 166 suspected deaths across 58 districts. The outbreak concentrated in two divisions that held 56.5 percent of cases, with children under five making up 81 percent and 72 percent of cases having received zero doses. National MR1 coverage fell from 88.6 percent to 86 percent and MR2 from 89 percent to 80.7 percent between 2019 and 2024, leaving roughly 20 million children vulnerable. The paper states that the resurgence reflects these accumulated immunity gaps from subnational inequities and programme disruption rather than vaccine failure.

What carries the argument

Rapid mixed-evidence review of aggregated surveillance data from WHO, UNICEF, DGHS, and media sources that tracks case counts, vaccination status, and coverage trends to identify immunity gaps as the transmission driver.

If this is right

  • Targeted vaccination campaigns are required in the most affected divisions and among zero-dose children to close immunity gaps.
  • Vitamin A supplementation must be restored as part of the outbreak response.
  • Paediatric care capacity needs strengthening to manage severe cases and prevent deaths.
  • Real-time surveillance should be integrated into ongoing outbreak response to guide further action.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • Other countries recovering from pandemic-related immunization disruptions may face similar concentrated outbreaks if subnational coverage inequities are not addressed.
  • Focusing recovery efforts on the lowest-coverage districts rather than uniform national targets could interrupt transmission more efficiently.
  • Follow-up studies measuring case incidence after targeted campaigns would test whether closing the identified zero-dose gaps reduces spread as expected.

Load-bearing premise

The aggregated surveillance data from WHO, UNICEF, DGHS, and media sources accurately captures true case numbers, vaccination status, and causes without major underreporting, misdiagnosis, or selection bias.

What would settle it

Finding that a large share of confirmed cases had received two valid doses of measles-rubella vaccine, or detecting vaccine-escape virus variants in sequenced samples from the outbreak, would indicate vaccine failure rather than immunity gaps.

Figures

Figures reproduced from arXiv: 2604.25951 by Alvi Ahmed Sarker, Faizunnesa Khondaker, Md. Kamrujjaman, Nuzhat Nuari Khan Rivu.

Figure 1
Figure 1. Figure 1: illustrates variations in reported disease burden and routine vaccination coverage across WHO regions from 2017 to 2024 view at source ↗
Figure 2
Figure 2. Figure 2: Monthly reported measles cases by WHO region in 2025 and 2026. The early-2026 pattern shows increasing reported burden in the Americas and South-East Asia, with lower totals than the 2025 peak but persistent multi-regional activity. 2.2 Current Measles Situation in Bangladesh Bangladesh is experiencing a fast-growing measles outbreak that intensified from mid-March 2026, with rapid geographic spread and hi… view at source ↗
Figure 3
Figure 3. Figure 3: Division-wise geographic distribution of cumulative reported measles cases and deaths in Bangladesh from 15 March to 15 April 2026. Numbers on each map indicate the total counts recorded in each division during the reporting period. 6 view at source ↗
Figure 4
Figure 4. Figure 4: Yearly trends in reported measles cases, incidence rate, and first-dose and second-dose measles￾rubella coverage in Bangladesh. The figure shows that long-term gains in coverage broadly coincided with lower disease burden but did not prevent renewed outbreak risk when coverage and equity weakened view at source ↗
Figure 5
Figure 5. Figure 5: Daily confirmed measles cases and confirmed deaths by division in Bangladesh in April 2026. Stacked bars represent confirmed cases, and labels above bars indicate confirmed deaths recorded on that day. The outbreak is overwhelmingly pediatric. UNICEF’s Bangladesh measles situation report 7 view at source ↗
Figure 6
Figure 6. Figure 6: Bangladesh measles burden in historical context. Annual WHO-reported measles cases are shown with a three-year moving average. The 2026 suspected and confirmed values are plotted separately as partial￾year outbreak comparison points. 4.2 Geographic distribution and concentration The outbreak burden was concentrated in a limited number of divisions rather than spread evenly across the country view at source ↗
Figure 7
Figure 7. Figure 7: Division-wise measles reporting in Bangladesh from the 31 March 2026 reporting slice. Dhaka accounted for the largest share of reported cases, followed by Rajshahi and Chattogram view at source ↗
Figure 8
Figure 8. Figure 8: Pareto analysis of division-wise measles reporting. Bars indicate division-level reported cases and the line shows the cumulative share of total burden in the reporting slice. The inset summarises the share held by the top two and top three divisions and the HHI value. 11 view at source ↗
Figure 9
Figure 9. Figure 9: Composition of the 2026 Bangladesh measles outbreak. The upper grouped bar shows the age distribution of reported cases and the lower grouped bar shows vaccination status among reported cases. 4.4 Immunisation programme context and emergency response Programme indicators showed that Bangladesh entered 2026 with declining protection even before the outbreak accelerated. Partner reports described valid first… view at source ↗
read the original abstract

\textbf{Background} Measles has resurged globally in the post-pandemic period as routine immunisation recovery remains below the two-dose threshold required to interrupt transmission. Bangladesh, previously nearing measles--rubella elimination, entered 2026 with widening coverage gaps, depleted vaccine stocks, and increasing numbers of missed children. We conducted a situation analysis to assess the scale, concentration, and programmatic implications of the outbreak. \textbf{Methods} We performed a rapid mixed-evidence review from 1--15 April 2026 using data from WHO, UNICEF, DGHS bulletins, PubMed/MEDLINE, ReliefWeb, SEARO updates, and Bangla-language media. Of 46 records screened, 19 were included. Analysis was based on aggregated, publicly available surveillance and programme data. \textbf{Findings} By 15 April 2026, Bangladesh reported 19{,}161 suspected cases, 2{,}973 confirmed cases, 166 suspected deaths, and 32 confirmed deaths across 58 districts since 15 March 2026. The outbreak was spatially concentrated: the top two divisions accounted for 56.5\% of cases (HHI = 0.217). Children under five comprised 81\% of cases, including 34\% infants under nine months. Vaccination status showed 72\% zero-dose and 16\% partially vaccinated cases. Coverage declined from 88.6\% to 86\% for MR1 and from 89\% to 80.7\% for MR2 (2019--2024), leaving about 20 million children vulnerable. \textbf{Interpretation} The resurgence reflects accumulated immunity gaps rather than vaccine failure, driven by subnational inequities and programme disruption. Urgent priorities include targeted vaccination campaigns, restoration of vitamin A supplementation, strengthening paediatric care capacity, and integrating real-time surveillance into outbreak response.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 2 minor

Summary. The manuscript conducts a rapid mixed-evidence review of publicly available data to describe a measles resurgence in Bangladesh starting March 2026. It reports 19,161 suspected cases and 2,973 confirmed cases across 58 districts, with 81% of cases in children under five, 72% zero-dose, and 16% partially vaccinated. The analysis concludes that the outbreak is driven by accumulated immunity gaps from declining MR1 and MR2 coverage (to 86% and 80.7%) and subnational inequities, rather than vaccine failure, and outlines urgent response priorities.

Significance. If the surveillance data accurately reflect vaccination status and case ascertainment, this situational analysis offers a timely compilation of outbreak metrics that could guide immediate public health actions in Bangladesh and contribute to understanding post-pandemic measles dynamics. The use of the Herfindahl-Hirschman Index for spatial concentration and the quantification of vulnerable children provide concrete figures for planning. However, as a descriptive review without new empirical validation, its long-term scientific impact is modest compared to studies with primary data or modeling.

major comments (2)
  1. [Methods] The methods describe a rapid review of aggregated data from WHO, UNICEF, DGHS, PubMed, ReliefWeb, and media but provide no details on how vaccination status was ascertained or validated in the 2,973 confirmed cases (e.g., via immunization cards, registry linkage, or bias adjustment). This is load-bearing for the central claim in the Interpretation section that the resurgence reflects immunity gaps rather than vaccine failure, as media and aggregated reports often over-represent unvaccinated severe cases.
  2. [Findings / Interpretation] The assertion that the outbreak is due to immunity gaps 'rather than vaccine failure' relies solely on the observed vaccination status distribution (72% zero-dose, 16% partial) without presenting data on vaccine effectiveness, cold-chain integrity, or comparisons to expected attack rates in vaccinated populations. The 12% of cases with presumed full vaccination status could indicate failure or misclassification, but no analysis addresses this.
minor comments (2)
  1. [Abstract] The abstract uses LaTeX-style formatting for large numbers (e.g., 19{,}161); this should be rendered consistently as 19,161 in the published version for readability.
  2. [Full text] Ensure that all data sources are explicitly cited with dates and URLs where possible, as the rapid review includes media sources that may require verification.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for the constructive comments. We have revised the manuscript to address the concerns by expanding the Methods section on data provenance and by moderating the language in the Interpretation to reflect the descriptive, secondary-data nature of the analysis.

read point-by-point responses

  1. Referee: [Methods] The methods describe a rapid review of aggregated data from WHO, UNICEF, DGHS, PubMed, ReliefWeb, and media but provide no details on how vaccination status was ascertained or validated in the 2,973 confirmed cases (e.g., via immunization cards, registry linkage, or bias adjustment). This is load-bearing for the central claim in the Interpretation section that the resurgence reflects immunity gaps rather than vaccine failure, as media and aggregated reports often over-represent unvaccinated severe cases.

    Authors: We agree that the Methods section requires greater transparency. The vaccination status figures are taken directly from aggregated DGHS surveillance bulletins, which do not include the underlying case-investigation protocols or validation methods. We have revised the Methods to state explicitly that 'vaccination status is as reported in the aggregated surveillance data without independent verification' and have added a Limitations paragraph acknowledging potential reporting biases, including possible over-representation of unvaccinated severe cases, and the absence of bias-adjustment procedures. revision: yes

  2. Referee: [Findings / Interpretation] The assertion that the outbreak is due to immunity gaps 'rather than vaccine failure' relies solely on the observed vaccination status distribution (72% zero-dose, 16% partial) without presenting data on vaccine effectiveness, cold-chain integrity, or comparisons to expected attack rates in vaccinated populations. The 12% of cases with presumed full vaccination status could indicate failure or misclassification, but no analysis addresses this.

    Authors: The referee is correct that the original phrasing was overly definitive given the data available. The 12% of cases reported as fully vaccinated may represent vaccine failure, cold-chain compromise, or misclassification, none of which can be assessed with the aggregated sources used. We have revised the Interpretation to state that the resurgence is 'primarily driven by accumulated immunity gaps... although vaccine failure or misclassification cannot be excluded for a minority of cases.' We have also added a forward-looking statement on the need for vaccine-effectiveness studies in the response priorities section. revision: partial

Circularity Check

0 steps flagged

No circularity: purely descriptive compilation of external surveillance data with no derivations or self-referential steps

full rationale

The paper is a rapid mixed-evidence situational analysis that aggregates and interprets publicly reported numbers (suspected/confirmed cases, deaths, vaccination status, coverage trends) from independent external sources (WHO, UNICEF, DGHS, media). No equations, models, fitted parameters, predictions, or mathematical derivations appear anywhere. The central interpretation (resurgence reflects immunity gaps) is a direct reading of the observed 72% zero-dose and 16% partially-vaccinated distribution among confirmed cases, not a reduction of any output to its own inputs by construction. No self-citations, uniqueness theorems, or ansatzes are invoked to support load-bearing claims. This matches the default expectation of a non-circular descriptive report.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

This is a descriptive observational report drawing on standard public health surveillance data. No free parameters, axioms, or invented entities are introduced or required for the central claims.

pith-pipeline@v0.9.0 · 5672 in / 1121 out tokens · 42853 ms · 2026-05-08T12:51:51.911120+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

32 extracted references · 6 canonical work pages

  1. [1]

    Immunization agenda 2030: Mid-point review

    World Health Organization. Immunization agenda 2030: Mid-point review. Technical re- port, World Health Organization, Geneva, 2025. URLhttps://www.who.int/publications/ m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind. Ac- cessed 11 April 2026

    2030

  2. [2]

    Measles deaths down 88% since 2000, but cases surge, November 2025

    World Health Organization. Measles deaths down 88% since 2000, but cases surge, November 2025. URLhttps://www.who.int/news/item/ 28-11-2025-measles-deaths-down-88--since-2000--but-cases-surge. Accessed 11 April 2026

    2000

  3. [3]

    World Health Organization and UNICEF. Progress and challenges with achieving universal immunization coverage: 2025 WUENIC estimates.https://data.unicef.org/resources/ data_explorer/unicef_f/?ag=UNICEF&df=GLOBAL_DATAFLOW&ver=1.0&dq=.IM_MCV1+IM_ MCV2..&startPeriod=2000&endPeriod=2024, July 2025. Accessed 11 April 2026

    2025

  4. [4]

    WHO south-east Asia region epidemiological bulletin, 7th edition

    World Health Organization Regional Office for South-East Asia. WHO south-east Asia region epidemiological bulletin, 7th edition. Technical report, WHO SEARO, New Delhi, April 2026. URLhttps://cdn.who.int/media/docs/default-source/searo/whe/wherepib/2026_07_ searo_epi_bulletin.pdf. Accessed 11 April 2026

    2026

  5. [5]

    Progress toward measles elimination — Bangladesh, 2000–2016.MMWR Morbidity and Mortality Weekly Report, 66(28):753–757,

    Sudhir Khanal, Rajendra Bohara, Stephen Chacko, Mohammad Sharifuzzaman, Mohammad Shamsuzzaman, James L Goodson, Alya Dabbagh, Katrina Kretsinger, Deepak Dhongde, Jayantha Liyanage, Sunil Bahl, and Arun Thapa. Progress toward measles elimination — Bangladesh, 2000–2016.MMWR Morbidity and Mortality Weekly Report, 66(28):753–757,

    2000

  6. [6]

    doi: 10.15585/mmwr.mm6628a3

    work page doi:10.15585/mmwr.mm6628a3

  7. [7]

    Evaluation of impact of measles rubella campaign on vaccination 15 coverage and routine immunization services in Bangladesh.BMC Infectious Diseases, 16: 411, 2016

    Md Jasim Uddin, Gourab Adhikary, Md Wazed Ali, Syed Ahmed, Mohammad Shamsuzza- man, Chris Odell, et al. Evaluation of impact of measles rubella campaign on vaccination 15 coverage and routine immunization services in Bangladesh.BMC Infectious Diseases, 16: 411, 2016. doi: 10.1186/s12879-016-1758-x. URLhttps://link.springer.com/article/ 10.1186/s12879-016-1758-x

    work page doi:10.1186/s12879-016-1758-x 2016

  8. [8]

    Leaving no child behind: a step closer to elimina- tion of measles and rubella from Bangladesh, December 2020

    World Health Organization Bangladesh. Leaving no child behind: a step closer to elimina- tion of measles and rubella from Bangladesh, December 2020. URLhttps://www.who.int/ bangladesh/news/detail/30-12-2020-leaving-no-child-behind. Accessed 11 April 2026

    2020

  9. [9]

    Bangladesh: WHO and UNICEF estimates of immunization coverage: 2023 revision

    World Health Organization and United Nations Children’s Fund. Bangladesh: WHO and UNICEF estimates of immunization coverage: 2023 revision. Technical report, WHO/UNICEF, Geneva/New York, July 2024. URLhttps://cdn.who.int/media/ docs/default-source/country-profiles/immunization/2024-country-profiles/ immunization-2024-bgd.pdf. Accessed 2026-04-21

    2023

  10. [10]

    Feldstein et al

    Lisa R. Feldstein et al. Vaccination coverage survey and seroprevalence among forcibly dis- placed rohingya children, cox’s bazar, bangladesh.PLOS Medicine, 2020. URLhttps: //journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003071

    work page doi:10.1371/journal.pmed.1003071 2020

  11. [11]

    Global resurgence in measles.The Lancet Microbe, 2026

    The Lancet Microbe. Global resurgence in measles.The Lancet Microbe, 2026. doi: 10.1016/ S2666-5247(26)00002-9. URLhttps://www.thelancet.com/journals/lanmic/article/ PIIS2666-5247(26)00002-9/fulltext. Accessed 11 April 2026

    2026

  12. [12]

    Accelerating measles and rubella elimina- tion in Southeast Asia.The Lancet Regional Health – Southeast Asia, 2025

    The Lancet Regional Health – Southeast Asia. Accelerating measles and rubella elimina- tion in Southeast Asia.The Lancet Regional Health – Southeast Asia, 2025. doi: 10.1016/ S2772-3682(25)00153-2. URLhttps://www.thelancet.com/journals/lansea/article/ PIIS2772-3682(25)00153-2/fulltext. Accessed 11 April 2026

    2025

  13. [13]

    Measles outbreak in Bangladesh, 21 children dead in March, questions over vaccine shortage, March 2026

    Shishir Moral. Measles outbreak in Bangladesh, 21 children dead in March, questions over vaccine shortage, March 2026. URLhttps://en.prothomalo.com/bangladesh/t7gt89boos. Prothom Alo (English edition); Accessed 11 April 2026

    2026

  14. [14]

    Measles: 38 children dead in Bangladesh outbreak.BMJ, 393:s654, 2026

    BMJ. Measles: 38 children dead in Bangladesh outbreak.BMJ, 393:s654, 2026. doi: 10.1136/ bmj.s654. URLhttps://www.bmj.com/content/393/bmj.s654. Accessed 11 April 2026

    2026

  15. [15]

    Bangladesh measles outbreak situation report no

    UNICEF Bangladesh. Bangladesh measles outbreak situation report no. 1, 08 april 2026. Technical report, UNICEF, April 2026. URLhttps://reliefweb.int/report/bangladesh/ unicef-bangladesh-measles-outbreak-situation-report-no-1-08-april-2026. Re- liefWeb posting. Accessed 11 April 2026

    2026

  16. [16]

    Bangladesh faces vaccine shortage for 10 diseases: Health services secretary, March 2026

    The Business Standard. Bangladesh faces vaccine shortage for 10 diseases: Health services secretary, March 2026. URLhttps://www.tbsnews.net/bangladesh/health/ bangladesh-faces-vaccine-shortage-10-diseases-health-secretary-1398836. Ac- cessed 11 April 2026

    2026

  17. [17]

    Bangladesh launches measles vaccination drive as child death toll passes 100, April 2026

    Hannah Ellis-Petersen. Bangladesh launches measles vaccination drive as child death toll passes 100, April 2026. URLhttps://www.theguardian.com/world/2026/apr/07/ bangladesh-measles-vaccination-drive-child-death-toll. The Guardian; Accessed 11 April 2026. 16

    2026

  18. [18]

    Measles, November 2025

    World Health Organization. Measles, November 2025. URLhttps://www.who.int/ news-room/fact-sheets/detail/measles. Updated 28 November 2025; Accessed 2026-04- 21

    2025

  19. [19]

    Measles cases surge worldwide, infecting 10.3 million people in 2023, November 2024

    World Health Organization. Measles cases surge worldwide, infecting 10.3 million people in 2023, November 2024. URLhttps://www.who.int/ news/item/14-11-2024-measles-cases-surge-worldwide--infecting-10. 3-million-people-in-2023. Accessed 2026-04-21

    2023

  20. [20]

    WHO immunization data portal: Provisional measles and rubella data, 2026

    World Health Organization. WHO immunization data portal: Provisional measles and rubella data, 2026. URLhttps://immunizationdata.who.int/global?location=&topic= Provisional-measles-and-rubella-data. Accessed 2026-04-21

    2026

  21. [21]

    WHO south-east Asia region epidemiological bulletin

    World Health Organization Regional Office for South-East Asia. WHO south-east Asia region epidemiological bulletin. Technical report, WHO SEARO, New Delhi, April 2026. URLhttps://cdn.who.int/media/docs/default-source/searo/whe/wherepib/2026_07_ searo_epi_bulletin.pdf. Accessed 2026-04-21

    2026

  22. [22]

    Press releases, 2026

    Directorate General of Health Services. Press releases, 2026. URLhttps://dghs.gov.bd/ pages/press-releases. Accessed 2026-04-21

    2026

  23. [23]

    Frequently asked questions about measles in Bangladesh, April 2026

    UNICEF Bangladesh. Frequently asked questions about measles in Bangladesh, April 2026. URLhttps://www.unicef.org/bangladesh/en/stories/ frequently-asked-questions-about-measles-bangladesh. Accessed 2026-04-21

    2026

  24. [24]

    Nationwide response mobi- lized to contain measles outbreak in Bangladesh, April 2026

    World Health Organization Regional Office for South-East Asia. Nationwide response mobi- lized to contain measles outbreak in Bangladesh, April 2026. URLhttps://www.who.int/ southeastasia/news/detail/15-04-2026-response-measlesBN. Accessed 2026-04-21

    2026

  25. [25]

    Bangladesh humanitarian situation report no

    UNICEF Bangladesh. Bangladesh humanitarian situation report no. 1 (measles outbreak). Technical report, UNICEF, Dhaka, April 2026. URLhttps://www.unicef.org/media/ 179846/file/Bangladesh-Humanitarian-Situation-Report-No.1%28Measles-Outbreak% 29-8-April-2026.pdf. Accessed 2026-04-21

    2026

  26. [26]

    Press releases and daily measles surveil- lance bulletins.https://dghs.gov.bd/pages/press-releases, 2026

    Directorate General of Health Services, Bangladesh. Press releases and daily measles surveil- lance bulletins.https://dghs.gov.bd/pages/press-releases, 2026. Accessed 11–15 April 2026

    2026

  27. [27]

    Bangladesh launches emergency measles– rubella campaign with UNICEF, WHO and Gavi to protect over 1.2 million children, April 2026

    World Health Organization Bangladesh. Bangladesh launches emergency measles– rubella campaign with UNICEF, WHO and Gavi to protect over 1.2 million children, April 2026. URLhttps://www.who.int/bangladesh/news/detail/ 05-04-2026-bangladesh-launches-emergency-measles-rubella-campaign-with-unicef--who-2-million-children. Accessed 11 April 2026

    2026

  28. [28]

    BGD: Epidemic — 03-2026 — measles in Bangladesh

    International Federation of Red Cross and Red Crescent Societies. BGD: Epidemic — 03-2026 — measles in Bangladesh. Technical report, IFRC GO, April 2026. URLhttps://go.ifrc. org/field-reports/18266. Accessed 11 April 2026. 17

    2026

  29. [29]

    Bangladesh measles outbreak (dg echo, media, dghs, ifrc, unicef) - echo daily flash of 7 april 2026, 2026

    ReliefWeb. Bangladesh measles outbreak (dg echo, media, dghs, ifrc, unicef) - echo daily flash of 7 april 2026, 2026. URLhttps://reliefweb.int/report/bangladesh/ bangladesh-measles-outbreak-dg-echo-media-dghs-ifrc-unicef-echo-daily-flash-7-april-2026. Accessed 2026-04-13

    2026

  30. [30]

    Buckee, and Ayesha S

    Taylor Chin, Caroline O. Buckee, and Ayesha S. Mahmud. Quantifying the success of measles vaccination campaigns in the rohingya refugee camps.Epidemics, 30:100385, 2020. doi: 10.1016/j.epidem.2020.100385. URLhttps://www.sciencedirect.com/science/article/ pii/S1755436519301331. Open access via PubMed Central

    work page doi:10.1016/j.epidem.2020.100385 2020

  31. [31]

    Akramuzzaman, Felicity T

    Syed M. Akramuzzaman, Felicity T. Cutts, Md J. Hossain, Obaidullah K. Wahedi, Nazmun Nahar, Darul Islam, Narayan C. Shaha, and Dilip Mahalanabis. Measles vaccine effectiveness and risk factors for measles in Dhaka, Bangladesh.Bulletin of the World Health Organization, 80(10):776–782, 2002. doi: 10.1590/S0042-96862002001000005. URLhttps://pmc.ncbi.nlm. nih...

    work page doi:10.1590/s0042-96862002001000005 2002

  32. [32]

    Sayi, Umid M

    Takudzwa S. Sayi, Umid M. Sharapov, Zachary Matson, Melissa M. Coughlin, et al. Im- munogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial.The Lancet Child & Adolescent Health, 9 (5):306–314, 2025. doi: 10.1016/S2352-4642(25)00090-2. URLhttps://www.sciencedirect. com/science...

    work page doi:10.1016/s2352-4642(25)00090-2 2025